Board summary
Key figures
53,994
Registered population
58.3% aged 18–64
22.5%
Aged 65+
ICB 19.0% · England 17.9%
5.9%
Ethnic minority (non-White)
2.8% Asian · England 9.6%
3.4%
In IMD quintile 1
ICB 31.9% · England 21.0%
~2,375
Core20 residents (est.)
Resident basis; registered basis ~1,997 · see page 3
8,414
Hypertension register
+6.34% in 3 yrs · England +5.60%
351
SMI register
15.8% of Warrington (LAD)'s
661
COPD register
Reviews +5.06% in 3 yrs
Forecast to 2030
9,739
Hypertension patients, 2030
+1,325 on today
57.9%
QRISK ≥20% on statins, 2030
+1.86pp over 3 yrs
5.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual review coverage trails England.
Coverage fell 8.9% over 2023 to 2025 (England +4.4%), leaving an estimated 1,625 patients unreviewed, which may reflect recall gaps.
High-risk lipid therapy below England benchmark.
Patients with QRISK ≥ 20% on lipid-lowering therapy trail Warrington (LAD) (61.6%) and England (63.6%), which could reflect recall or prescribing gaps.
Hypertension control improved faster than England.
Treatment to target rose +16.9% over 2023 to 2025 (England +3.6%), though current achievement of 64.0% remains below England's 70.3%.
Population, age and ethnicity
Aged 65+ patients represent 22.5% of the list, exceeding England's 17.9% benchmark
South Warrington PCN has 53,994 registered patients. The population is older than comparators: 22.5% (12,134 patients) are aged 65+, compared to Warrington LAD (17.5%), the ICB (19.0%), and England (17.9%), while 58.3% are aged 18-64 and 19.2% aged 0-17. Census resident data records 94.1% White ethnicity, compared to Warrington LAD (93.5%), the ICB (93.0%), and England (81.1%), with a 5.9% ethnic minority share. Projected list growth to 2030 is 1.4% under an unverified methodology. Age figures reflect registered patients; ethnicity reflects Census residents.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Warrington (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Warrington LA) | 1,737 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 76.9% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.7% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Warrington LA) | 905 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Warrington LA) | 12.1 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
PCN Core20 deprivation averages 3.4% but reaches 23.8% at Latchford Medical Centre
South Warrington PCN averages IMD decile 8.3 (England 5.5) with 3.4% of registered patients in the Core20 cohort, below Warrington (16.9%), England (21.0%), and the ICB (31.9%). Weighted practice share is 3.7% (a 0.27 pp discrepancy against the PCN rate). Deprivation is concentrated at Latchford Medical Centre, with a 23.8% share (an estimated 1,997 patients), while Brookfield Surgery, Stockton Heath Med.centre, The Lakeside Surgery, and Stretton Medical Centre each record 0.0%. Targeted inequalities resources should focus on Latchford Medical Centre to address the PCN's concentrated Core20 cohort.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
351
SMI register
0.65% recorded prevalence
218
Learning disability register
0.40% recorded prevalence
23
Care homes, 956 beds
In the PCN catchment
9.4%
Provide unpaid care
Warrington (LAD), Census 2021
Learning disability prevalence is 0.4% (218 patients) and severe mental illness is 0.7% (351 patients), below Warrington LAD (0.5% and 1.0%) and England (0.6% and 1.0%). Catchment infrastructure includes 23 care homes with 956 beds, though resident registrations are unconfirmed; Warrington borough records 9 rough sleepers (autumn 2025). Lower recorded prevalence may reflect coding practice or case-finding variation; practice register audits would be required to verify clinical case detection.
Severe mental illness: physical health checks
For SMI physical checks, 87.0% had blood pressure recorded (England 83.4%) and 85.8% had BMI recorded (England 82.1%). Smoking cessation support was 90.3%, below England (94.2%), Warrington (93.7%), and the ICB (95.2%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,414
Hypertension register
+6.34%
Register growth, 3 yrs
Warrington (LAD) +6.41% · England +5.60%
+8.25pp
BP control, under 80
≤140/90 · +7.94pp aged 80+
+1,325
More patients by 2030
Forecast 9,739 (17.54%)
Hypertension case-finding and control
Hypertension prevalence is 15.5% (8,414 patients), exceeding England (15.2%) but below Warrington (16.4%) and the ICB (16.8%), giving an unadjusted register gap range of -191 to +445 patients. Patients treated to target reached 64.0% following a +16.9% three-year change (England +3.6%), yet overall control lags England (70.3%), Warrington (68.7%), and the ICB (69.1%). Recent blood pressure recording is 82.0% against 90.0% in England, with control under age 80 at 61.2% (England 67.8%) and aged 80+ at 73.3% (England 81.2%). Hypertension control trails national benchmarks despite recent improvement, which may suggest a role for structured recall for under-controlled patients.
Lipids and statins
QRISK ≥ 20% lipid therapy is 54.0% (England 63.6%, Warrington 61.6%, ICB 63.2%). Statin treatment in diabetes without CVD is 66.6% (England 73.2%), with three-year change at -1.3% (England +2.1%). Lower uptake across cohorts compared with England benchmarks could reflect review differences, subject to local audit.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 82,429 | £1.50 | £1.71 | £1.86 | £123,644 |
| Cardiovascular (all), 2025 | 123,936 | £4.92 | £4.37 | £3.33 | £609,765 |
In 2026, the PCN prescribed 82,429 lipid-regulating drug items at £1.50 per item, below Warrington (£1.59), the ICB (£1.71), and England (£1.86), spending £29,674 less than at England's unit cost across £123,644 total spend.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−8.94%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.88%
Asthma prevalence, PCN 3-yr % change
Asthma 12-month review coverage fell 8.9% over 2023 to 2025 (England +4.4%) to 51.0% (Warrington 61.4%, ICB 62.3%, England 65.7%), leaving about 1,600 (1,625) of 3,320 patients unreviewed. Second-hand smoke recording in asthma (6-19 yrs) was 63.9% (219 patients), below England (78.8%). COPD prevalence is 1.2% (661 patients) versus 1.8% in Warrington and 1.9% in England (unadjusted gap +323 to +362), while COPD review coverage is 71.6% (England 76.4%). Slower review delivery could reflect recall capacity constraints, unverified locally.
Cancer register and children's immunisation
Cancer prevalence is 4.3% (2,312 patients; England 3.8%, Warrington 3.9%), rising +12.4% over 2023 to 2025 (England +9.0%). In childhood immunisations, 12-month 6-in-1 uptake is 95.8%, exceeding the 95.0% target. By age five, MMR dose 2 reaches 92.6% (below target by 2.4 pp; 3.3 pp below dose 1) and the 4-in-1 booster is 90.2% (below target by 4.8 pp), though both exceed England (82.8% and 80.9%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of cancers with a known stage (7,482 of 13,490) across NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.5 pp below the 75.0% national ambition by 2028. Staging coverage was 72.8% (13,490 of 18,522). Reaching the 75.0% ambition requires about 2,640 extra early-stage diagnoses annually, while early-stage share rose 2.6 pp from 52.8% in 2013. Site rates were 22.0% for oesophagus and 87.1% for breast. At PCN level, cervical screening in women aged 25-49 is 74.4% (England 66.8%), with Latchford Medical Centre at 72.4% and Stretton Medical Centre at 72.9%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 data, North Cheshire and Mersey NHS Foundation Trust achieved 83.7% on the 62-day cancer standard, 1.3 pp below the 85.0% standard but above Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%), Manchester University NHS Foundation Trust (72.8%), the ICB (76.2%) and England (71.2%). The trust met the 28-day faster diagnosis (80.2%) and 31-day treatment (98.2%) standards. Diagnostic 6+ week waits were 0.5% for MRI and 2.3% for CT, though echocardiography was 28.0%. These figures reflect provider pathway performance rather than PCN delivery, indicating local secondary diagnostic access.
| Pathways within standard (%) | North Cheshire and Mersey | Mersey and West Lancashire | Manchester | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.21 | 72.39 | 80.06 | 77.25 | 79.32 |
| 31-day treatment (96%) | 98.17 | 95.46 | 92.54 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 83.67 | 77.96 | 72.85 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | North Cheshire and Mersey | Mersey and West Lancashire | Manchester | England |
|---|---|---|---|---|
| MRI | 0.53 | 14.04 | 11.68 | 21.40 |
| CT | 2.32 | 13.08 | 14.66 | 9.92 |
| Echocardiography | 28.04 | 34.88 | 4.91 | 28.48 |
| Colonoscopy | 15.98 | 18.04 | 4.51 | 30.83 |
| Gastroscopy | 20.24 | 18.17 | 29.35 | 29.02 |
| All 15 DM01 tests | 6.34 | 21.17 | 8.98 | 23.14 |
| Community services activity | Warrington residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 38,550 | 541,280 |
| Referrals | 7,320 | 97,150 |
| Patients with a contact | 14,830 | 146,240 |
Community services (residents of Warrington), Jun 2026 (provisional). In provisional June 2026 Community Services Dataset records, 56% of community contacts for Warrington residents (21,595 of 38,550) were with adults aged 65 and over. These figures reflect borough-wide resident activity rather than PCN delivery, highlighting substantial community service reliance among older adults.
Practice variation and patient experience
Good practice experience varies by 28.8 pp and phone access spans 33.5 pp
In 2025/26, overall QOF achievement spanned from 85.4% at Stretton Medical Centre to 100.0% at Latchford Medical Centre and The Lakeside Surgery (England 92.5%). Vaccination and immunisation achievement showed a 32.1 pp spread, from 67.9% at Stockton Heath Med.centre and Stretton Medical Centre to 100.0% at Brookfield Surgery, while all-domain personalised care adjustments reached 20.8% at The Lakeside Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Brookfield Surgery | 112 | 0.0 | 49.7% | 69.6% | 83.9% |
| Stockton Heath | 132 | 0.0 | 29.0% | 68.1% | 73.9% |
| Latchford | 90 | 23.8 | 56.5% | 59.1% | 64.5% |
| Stretton | 118 | 0.0 | 42.8% | 70.5% | 62.1% |
| Lakeside | 121 | 0.0 | 22.9% | 54.0% | 55.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven tracked measures trail national three-year progress, led by falling asthma reviews
Across 25 tracked trend measures, 11 trail England over 2023 to 2025. Slower chronic reviews lead trailing indicators: asthma reviews fell 8.9% (England +4.4%), and non-frail diabetes HbA1c control fell 3.7% (England +4.4%). Mental health BMI checks rose +0.7 pp (England +5.1 pp). In contrast, hypertension treated to target rose +16.9% (England +3.6%), and blood pressure control under age 80 rose +15.6% (England +3.2%). Slower review delivery may reflect recall bottlenecks, which practice recall audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
Diabetes HbA1c control
Heart failure reviews
Breast screening (53-70)
BMI record (SMI)
Hypertension treated to target
BP control, under 80
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Warrington (LAD) | Asset | PCN | Warrington (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 23 (956 beds) | n/a | Schools (catchment) | 64 | n/a |
| Children's centres | 3 | 12 | Places of worship | 48 | 89 |
| Libraries | 2 | 7 | Primary schools (LA maintained) | 14 | 28 |
| Primary academies | 11 | 31 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Asthma 12-month review coverage is 51.0% (Warrington 61.4%, ICB 62.3%, England 65.7%) after falling 8.9% over 2023 to 2025 (England +4.4%), leaving 1,625 of 3,320 patients unreviewed. For discussion: practices could run structured annual review recall using a standardised template, checking second-hand smoke status alongside inhaler prescribing. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension and lipid review recall
Hypertension prevalence is 15.5% (8,414 patients; Warrington 16.4%, England 15.2%; unadjusted gap -191 to +445). Target control is 64.0% (England 70.3%) and QRISK ≥ 20% lipid therapy is 54.0% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
COPD case-finding and review audit
COPD QOF prevalence is 1.2% (661 patients) versus 1.8% in Warrington, 1.9% in England, and 2.5% in the ICB (unadjusted gap +323 to +362), with 71.6% review coverage (England 76.4%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult frailty capacity review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation offer audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration protocol (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Access and triage workflow review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension and lipid review recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · COPD case-finding and review audit (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
